Payment overview · 2025
General Payments
$185.59
8 reported records · 8 companies
Healthcare provider profile · identity verified
Samuel Olaniyi Bada, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSON, TN · NPI 1770530586
Verified facts
What the public records show
CMS Open Payments records show Samuel Olaniyi Bada, M.D. received $185.59 in general payments during 2025 across 8 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $36.94 | 19.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.15 | 17.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.61 | 15.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.15 | 10.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.29 | 9.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.22 | 9.8% | 1 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $17.70 | 9.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.53 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $185.59 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $36.94 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $31.75 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| HYALGAN Normalized: hyalgan |
Device | Fidia Pharma USA Inc. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
159 | 37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 690 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 645 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 616 | 153 |
| Metformin Hcl | Metformin Hcl | 392 | 100 |
| Losartan Potassium | Losartan Potassium | 376 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 361 | 50 |
| Carvedilol | Carvedilol | 325 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 317 | 79 |
| Gabapentin | Gabapentin | 315 | 71 |
| Furosemide | Furosemide | 306 | 80 |
| Trazodone Hcl | Trazodone Hcl | 275 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 249 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 246 | 49 |
| Famotidine | Famotidine | 242 | 44 |
| Potassium Chloride | Potassium Chloride | 226 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 224 | 64 |
| Lisinopril | Lisinopril | 210 | 68 |
| Omeprazole | Omeprazole | 204 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 55 |
| Alendronate Sodium | Alendronate Sodium | 184 | 55 |
| Ozempic | Semaglutide | 177 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 55 |
| Eliquis | Apixaban | 169 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 167 | 40 |
| Farxiga | Dapagliflozin Propanediol | 159 | 37 |
| Oxycodone Hcl | Oxycodone Hcl | 155 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 147 | 37 |
| Sertraline Hcl | Sertraline Hcl | 147 | 16 |
| Levetiracetam | Levetiracetam | 146 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 140 | 15 |
| Montelukast Sodium | Montelukast Sodium | 137 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 133 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 124 | 27 |
| Allopurinol | Allopurinol | 123 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 54 |
| Linzess | Linaclotide | 104 | 33 |
| Tramadol Hcl | Tramadol Hcl | 101 | 32 |
| Glimepiride | Glimepiride | 97 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 95 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 14 |
| Divalproex Sodium | Divalproex Sodium | 94 | 14 |
| Clonidine Hcl | Clonidine Hcl | 93 | 32 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 92 | suppressed |
| Methadone Hcl | Methadone Hcl | 92 | suppressed |
| Simvastatin | Simvastatin | 92 | 22 |
| Januvia | Sitagliptin Phosphate | 90 | 13 |
| Methotrexate | Methotrexate Sodium | 89 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 24 |
| Donepezil Hcl | Donepezil Hcl | 82 | 18 |
| Dutasteride | Dutasteride | 80 | 21 |
| Pregabalin | Pregabalin | 77 | 16 |
| Buspirone Hcl | Buspirone Hcl | 76 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 55 |
| Jardiance | Empagliflozin | 76 | 24 |
| Alprazolam | Alprazolam | 75 | 15 |
| Labetalol Hcl | Labetalol Hcl | 74 | 17 |
| Xarelto | Rivaroxaban | 73 | 18 |
| Rybelsus | Semaglutide | 70 | 17 |
| Prednisone | Prednisone | 67 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 11 |
| Memantine Hcl | Memantine Hcl | 66 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 15 |
| Meloxicam | Meloxicam | 62 | 15 |
| Ezetimibe | Ezetimibe | 61 | 26 |
| Lovastatin | Lovastatin | 61 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 55 | 16 |
| Lansoprazole | Lansoprazole | 54 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 19 |
| Latanoprost | Latanoprost | 49 | 13 |
| Lactulose | Lactulose | 48 | 17 |
| Methylprednisolone | Methylprednisolone | 48 | 39 |
| Metoclopramide Hcl | Metoclopramide Hcl | 48 | 14 |
| Baclofen | Baclofen | 47 | 16 |
| Spironolactone | Spironolactone | 47 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 44 | 11 |
| Novolog | Insulin Aspart | 43 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 11 |
| Promethazine Hcl | Promethazine Hcl | 40 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | 15 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 37 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 31 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 23 |
| Benztropine Mesylate | Benztropine Mesylate | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Levemir | Insulin Detemir | 31 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Clonidine | Clonidine | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Calcium Acetate | Calcium Acetate | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 18 |
| Cilostazol | Cilostazol | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Repatha Syringe | Evolocumab | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 11 |
| Topiramate | Topiramate | 27 | 11 |
| Fluconazole | Fluconazole | 26 | 18 |
| Dexamethasone | Dexamethasone | 25 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 21 |
| Colchicine | Colchicine | 24 | suppressed |
| Etodolac | Etodolac | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 14 |
| Risperidone | Risperidone | 21 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Insulin Aspart | Insulin Aspart | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $185.59 · 8 records | Teva Pharmaceuticals USA, Inc. | Dexcom G6 Transmitter, HYALGAN, JARDIANCE, KRYSTEXXA, UZEDY, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error